Clinical Trial Update: A Phase II Trial of Florbetapir (18F) Positron Emission Tomography (PET) Imaging in Japan of Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD) [Phase 2, Phase 3]

View source ↗

Summary

This is a Phase II/III trial update of Florbetapir (18F) PET imaging conducted in Japan across healthy volunteers, mild cognitive impairment, and Alzheimer's di…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Cognitive Impairment

Drugs mentioned

• Florbetapir (18F) PET imaging agent (florbetapir)

Snippet

Sponsor: Avid Radiopharmaceuticals | Conditions: Alzheimer's Disease, Mild Cognitive Impairment | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2013-09-19